Superpower has introduced a clinician-prescribed peptide program pairing BPC-157, TB-500 and MOTS-c with its baseline panel of more than 100 biomarkers, wearable data and scheduled clinical follow-up, with shipping expected in late November 2026. The offering follows an interim Department of Health and Human Services policy indicating it does not intend to pursue enforcement against licensed pharmacies and physicians compounding these peptides under specified safeguards while FDA rulemaking proceeds. The compounds remain unapproved by the FDA, and human safety and efficacy data are limited.
Key Points
- BPC-157, TB-500 and MOTS-c prescribed after individual clinician evaluation
- Dosing tied to 100-plus biomarkers, wearables and recurring lab monitoring
- Compounded peptides remain FDA-unapproved with limited human efficacy evidence
Longevity Analysis
Pairing peptide administration with serial biomarker measurement addresses the central weakness of consumer peptide use, which is intervention without a baseline or a feedback loop. Compounds targeting tissue repair and mitochondrial signaling act on systems whose output is measurable, so repeat labs and wearable trends can distinguish genuine physiological response from expectation. The limited human evidence base makes structured monitoring and clinician oversight the determining variable in whether such programs produce interpretable results rather than accumulated exposure.
Original published by LT Wire.